AGENUS Agenus (AGEN) announced the upcoming launch of its Biotech Electronic Security Token (BEST); the first digital security offering in healthcare. Tokenization enables qualified investors to directly invest in a single biotech product while preserving shareholder equity. Garo Armen, Chairman and CEO of Agenus said, "Today, by announcing the first of its kind asset backed digital security offering in healthcare, we open the doors for a transformative …

Can a liquid biopsy test be accurate enough for physicians to rely on in differentiating between malignant and benign lung nodules in early stage lung cancer and probably other cancers?  A Yes answer has come out from OncoCyte Corporation (OCX) which announced positive results from its key R&D Validation study demonstrating the accuracy of the Company’s DetermaVu™ liquid biopsy test for lung cancer.  The R&D Validation study …

OncoCyte (OCX) has news. This firm, which develops non-invasive blood and urine liquid biopsy diagnostic tests has good news about its lung cancer liquid biopsy. Liquid biopsy is a term recently coined for a simple blood test that can replace current invasive and expensive biopsy procedures for the detection of cancers at their early stages. This simple blood test is expected to lessen the need …